Announcements Trials

Browse Landscape

Phase

Status

Completed 29 Terminated 10 Recruiting 5 Suspended 2 Withdrawn 1 Unknown 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 15 Gastrointestinal 7 Genitourinary 6 Endocrine 6 Tumor-Agnostic 4 Head & Neck 3 Sarcoma 2 Other solid neoplasm 2 Other hematologic neoplasm 2 NET 2 Thoracic 1 Other neoplasm 1 Lymphoid 1 Gynecologic 1 Dermatologic 1 CNS 1

Conditions

Diffuse Intrinsic Pontine Glioma 1

Interventions

Temozolomide 66 Radiotherapy 52 Carboplatin 25 Bevacizumab 21 Cisplatin 19 Radiosurgery 18 Vincristine 17 Etoposide 17 Cyclophosphamide 17 Surgical Procedures, Operative 13 Magnetic Resonance Spectroscopy 13 Chemotherapy, Adjuvant 11 Melphalan 10 Lomustine 10 Drug Therapy 10 Filgrastim 9 Erlotinib Hydrochloride 9 apatinib 8 Pemetrexed 8 3-Iodobenzylguanidine 8 anlotinib 7 Radiation 7 Peripheral Blood Stem Cell Transplantation 7 Methotrexate 7 Thiotepa 6 Isotretinoin 6 Irinotecan 6 Ifosfamide 6 Doxorubicin 6 Carmustine 6

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Unknown × Everolimus × CNS × Clear all

NCT02233049 2018-07-23

BIOMEDE

Gustave Roussy, Cancer Campus, Grand Paris

Phase 2 Unknown

Diffuse Intrinsic Pontine Glioma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡